Similarly, combining peripheral blood m6A modification levels with METTL14 and FTO regulatory genes achieved an AUC of 0.929 for breast cancer diagnosis, which was also better than the biomarkers CEA (0.599) and CA153 (0.572). The gene discussed is FTO; the disease is breast carcinoma.